The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Ono Set for Japan Filing of SK Bio’s Epilepsy Med in FY2025
Ono Pharmaceutical said on December 10 that its South Korean partner SK Biopharmaceuticals’ antiepileptic drug cenobamate delivered positive results in an Asian PIII program. The Japan firm, which has the domestic rights to the compound, is now poised to file…
To read the full story
Related Article
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
BUSINESS
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…